{
    "symbol": "ITRM",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 11:42:07",
    "content": " Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including uncertainties inherent in the design, initiation and conduct of clinical and non-clinical development, including the REASSURE clinical trial and non-clinical development being conducted trials in response to the CRL receipt in July 2021, the availability and timing of data from the REASSURE clinical trial and the ongoing non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, including the potential resubmission of our NDA, changes in public policy or legislation, commercialization plans and timelines, if oral sulopenem is approved, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of our expectations regarding how far into the future our cash on hand will fund our ongoing operations, and other risk factors set out in our filings with the SEC, including the quarterly report filed today."
}